Clinical trials: Liver Cell Carcinoma Non-resectable
Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
This phase II trial studies how well pevonedistat alone or in combination with chemotherapy (paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver.
- Conditions
- Metastatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT04175912
- Testing
- Carboplatin, Paclitaxel, Pevonedistat
- Where
- 419 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen…
- Trial name
- NCT06492395
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatobiliary Cancers
Observational Study Protocol: LIVER-R
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications.
- Trial name
- LIVER-R (NCT06252753)
- Testing
- Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings
- Where
- 161 sites in United States, Australia and 20 more
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma Non-resectable
Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma
Assessment of the long-term outcome of percutaneous ethanol alcohol injection (PEI) for the large and unresectable hepatocellular carcinoma: single center non-randomized trial.
- Trial name
- NCT03138031
- Testing
- Percutaneous ethanol alcohol injection
- Where
- Sudan
- Volunteers
- 23 people
- Sponsor
- The National Ribat University
Hepatocellular Carcinoma Non-resectable
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and iodion-125 seeds brachytherapy (TACE-Len-I) compared with TACE combined with lenvatinib (TACE-Len)…
- Trial name
- NCT04967495
- Testing
- TACE combined with lenvatinib and iodion-125 seeds brachytherapy, TACE combined with lenvatinib
- Where
- China
- Volunteers
- 171 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma
The primary aim of this exploratory study is to test the safety and tolerability of milciclib when administered orally at 100 mg in patients with recurrent or metastatic Hepatocellular Carcinoma.
- Trial name
- NCT03109886
- Testing
- Milciclib maleate
- Where
- 14 sites in Greece, Israel and 1 more
- Volunteers
- 31 people
- Sponsor
- Tiziana Life Sciences LTD
Liver Cancer
Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective for liver cancer.
- Trial name
- NCT00012324
- Testing
- doxorubicin hydrochloride, nolatrexed dihydrochloride
- Where
- 42 sites in United States, Canada and 1 more
- Sponsor
- Eximias Pharmaceutical
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum
- Trial name
- NCT00028496
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma
Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.
This study is a single-center, open-label Phase II clinical trial, aiming to enroll approximately 30 unresectable BCLC stage B or C hepatocellular carcinoma (HCC) patients from China.
- Trial name
- NCT06375486
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Unresectable Hepatocellular Carcinoma
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
This clinical trial was designed to evaluate the safety and efficacy of Y90-SIRT combined with nivolumab, ipilimumab, and lenvatinib in patients with unresectable HCC.
- Trial name
- NCT07482059
- Testing
- ttrium-90 microspheres in combination with nivolumab, ipilimumab, and lenvatinib in patients with unresectable hepatocellular carcinoma
- Where
- China
- Volunteers
- 33 people
- Sponsor
- West China Hospital
Combinational Immunotherapy, Hepatocellular Carcinoma Non-Resectable
Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma
The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous…
- Conditions
- Combinational Immunotherapy, Hepatocellular Carcinoma Non-Resectable, Hyperbaric Oxygen Therapy
- Trial name
- CCGLC-003 (NCT05031949)
- Testing
- hyperbaric oxygen therapy plus Camrelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhang Bi Xiang, MD
Hepatocellular Carcinoma
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
A study to determine how long ramucirumab (IMC-1121B) will stop cancer from growing in participants with liver cancer that cannot be treated with surgery.
- Trial name
- NCT00627042
- Testing
- Ramucirumab (IMC-1121B)
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Eli Lilly and Company
Liver, Cancer of, Non-Resectable
QuiremSpheres Observational Study
The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT…
- Trial name
- Hope166 (NCT03563274)
- Testing
- Selective Internal Radiation Therapy with QuiremSpheres®
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Terumo Europe N.V.
Unresectable Hepatocellular Carcinoma, Pembrolizumab
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.
HCC patients with PVTT (main trunk or the first-degree branch) treated with the combination of pembrolizumab (Ketruda), lenvatinib (Lenvima), and SBRT.
- Conditions
- Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib, Stereotactic Body Radiotherapy
- Trial name
- NCT05286320
- Testing
- Lenvatinib/Pembrolizumab plus SBRT combinations
- Where
- Taiwan
- Volunteers
- 27 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma Non-resectable
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of transarterial chemoembolization (TACE), Anti-VEGF antibodies or…
- Trial name
- CCGLC-008 (NCT05717738)
- Testing
- TACE, Lenvatinib, Anti-PD-1 monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
- Trial name
- NCT06911255
- Testing
- Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE)
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yoon Jun Kim
Hepatocellular Carcinoma Non-resectable
Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma
Patients with hepatocellular carcinoma often die from intrahepatic disease because current treatment options are limited. Local treatment using 166Ho-radioembolization (166Ho-RE) offers a safe and effective treatment.
- Trial name
- iHEPAR (NCT05114148)
- Testing
- Holmium-166 radioembolization
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer.
- Conditions
- Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03186898
- Testing
- Proton Therapy, Photon Therapy
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- NRG Oncology
Inoperable HCC
Hepatocellular Carcinoma (HCC)_Torisel_
This is a phase I/II study to evaluate dose limited toxicity and efficacy of Torisel
- Trial name
- NCT01251458
- Testing
- Torisel
- Where
- Hong Kong
- Volunteers
- 46 people
- Sponsor
- Chinese University of Hong Kong
Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma.
- Trial name
- NCT07391839
- Testing
- MDN-001 Injection(Yttrium-90 Microsphere Injection)
- Where
- 8 sites in China
- Volunteers
- 40 people
- Sponsor
- Suzhou Mednovo Yi Medical Technology Co., Ltd.